Overview MESUPRON®

Compound Class	Oral small molecule serine protease inhibitor
Indications	Currently pancreatic and breast cancer, additional indications including ovarian and colon cancer possible
Target	The uPA system has been shown to play a key role in tumour cell invasion and metastasis, as well as in primary tumour growth, of various solid tumours including breast, ovarian, gastric, colon and pancreatic cancer.
Mode of Action	Anti-metastatic, non-cytotoxic agent
Development Status	WILEX has developed the orally available drug candidate MESUPRON^®, as a pro-drug of WX-UK1. The drug candidates in the uPA programme, WX-UK1 and MESUPRON^®, are the first inhibitors of uPA in oncology trials worldwide. Eight different clinical trials with WX-UK1 and MESUPRON^® in several indications were successfully conducted. MESUPRON^® is currently being studied in a Phase II efficacy trial in the indication breast cancer.
Development Rationale	With oral MESUPRON^®, WILEX has developed a drug candidate to inhibit the Urokinase Plasminogen Activator (uPA) system. The uPA programme of WILEX can be considered as a promising new non-cytotoxic approach in cancer therapy to specifically block tumour metastasis in solid cancers.

Seite gelesen: 505 | Heute: 6